Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

benign prostatic hyperplasia

- PMLiVE

Astellas agrees €800m deal to buy Belgian biotech Ogeda

Will pay another €300m if fezolinetant meets clinical and regulatory targets

- PMLiVE

Astellas names Linda Friedman as EVP, general counsel

She is due to take up the role on 1 April

Deal Watch October 2016

Allergan, Astellas, AstraZeneca, Boehringer Ingelheim and Eli Lilly feature in this month's pharma deals round-up

- PMLiVE

Astellas buys Ganymed to boost immuno-oncology pipeline

Enters into €1.28bn deal for access to first-in-class gastric cancer blockbuster candidate

Astellas bolsters oncology clinical development leadership

Dr Steven Benner joins while Dr Anne Keating is promoted

- PMLiVE

Chiesi’s Holoclar wins UK Prix Galien orphan drug award

Novartis and Astellas also scoop prizes at the prestigious ceremony

Roche - Basel

Roche re-joins UK pharma’s trade body the ABPI

Firm left in 2009 following its suspension for a major Code of Practice breach 

Astellas launches digital health investment company

Will look for firms that focus on patient outcomes and offer pharma synergies

Biogen Idec building

Biogen buys into Ionis’ nusinersen after positive phase III trial

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 

Boehringer Ingelheim headquarters

Boehringer stops Gilotrif head and neck cancer trials

Trial data suggests the drug is “highly unlikely” to prolong patients’ remission

- PMLiVE

Astellas promotes John Demaree

He becomes vice president of oncology marketing, Americas

- PMLiVE

Former Sanofi exec Joseph Devaney joins Astellas

He becomes government affairs and policy, Americas VP

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links